Sysmex

Sysmex FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Sysmex (6869.T) as of Oct 10, 2026 is 115.48 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 109.97 % — a change of 5.01% (higher).

FCF Conversion

115.48 %

YoY

5.01%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Sysmex is 2026 115.48 % . FCF Conversion Rate (FCF/EBITDA) of Sysmex was 2025 109.97 % . It decreases by 5.01% higher compared to the previous year.

The Sysmex FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
63.11 JPY
Jan 1, 2020
113.39 JPY
Jan 1, 2021
147.14 JPY
Jan 1, 2022
104.26 JPY
Jan 1, 2023
112.16 JPY
Jan 1, 2024
77.15 JPY
Jan 1, 2025
109.97 JPY
Jan 1, 2026
115.48 JPY
The Sysmex FCF Conversion history
YEARFCF ConversionYoY
115.48 %+5.01%
109.97 %+42.55%
77.15 %-31.22%
112.16 %+7.57%
104.26 %-29.14%
147.14 %+29.76%
113.39 %+79.67%
63.11 %-30.60%
90.94 %+74.72%
52.05 %-27.27%
71.56 %-25.55%
96.13 %-15.05%
113.16 %—
Access this data via the Eulerpool API

Sysmex Stock analysis

What does Sysmex do? Sysmex Corp is a Japanese company that has been a leading provider of diagnostic and analytical laboratory systems and solutions for the healthcare industry since its founding in 1968. The company is headquartered in Kobe, Japan and employs over 9,000 people worldwide. History: Sysmex was founded by a group of young scientists in Japan who wanted to develop an automated blood cell analysis system to improve the high workload of manual blood analysis at the time. The company began developing this system and brought it to market in 1972. Business model: Sysmex focuses on the development, production, and sale of diagnostic systems and solutions for medical laboratories around the world. The company specializes in hematology, hemoglobinopathy, hemostasis, urinalysis, immunology, clinical chemistry, and molecular biology. Divisions: Sysmex Corp is divided into three main business divisions: 1. Diagnostic Systems: This division includes hematology, hemoglobinopathy, hemostasis, urinalysis, immunology, clinical chemistry, and molecular biology systems. Sysmex is one of the world's leading providers of hematology analysis devices and also offers molecular biology systems for the diagnosis and monitoring of infectious diseases and cancer. 2. Information Solutions: This division offers software and IT solutions that support laboratory management and the integration of laboratory data to optimize analysis processes. The company also offers solutions for automating laboratory processes and managing laboratory inventory. 3. Life Science: This division focuses on the development of products for the life sciences, particularly cell analysis and imaging, as well as production, processing, and storage of cell cultures. Sysmex is also involved in the production of devices for harvesting mesenchymal stem cells from adipose tissue. Products: Sysmex offers a variety of products, including: - Hematology analysis devices for determining blood cell parameters such as RBC, WBC, HGB, HCT, and platelets. - Hemostasis systems for analyzing blood coagulation. - Molecular biology systems for the diagnosis and monitoring of infectious diseases and cancer. - Urinalysis systems for analyzing urine samples for chemical and microscopic parameters. - Immunology analysis devices for determining specific proteins and antibodies in the blood. - Clinical chemistry analysis devices for analyzing chemical parameters in blood samples. - Software and IT solutions for optimizing laboratory processes and management. - Cell analysis and imaging systems for investigating cell morphology and functions. - Devices for harvesting mesenchymal stem cells from adipose tissue. In summary, Sysmex Corp is a global leader in diagnostic and analytical laboratory systems and solutions for the healthcare industry. In its nearly 50-year history, the company has developed and produced a wide range of products that enable laboratories to perform fast and accurate disease diagnosis. The company has also expanded its business into other areas such as information solutions and the life sciences. Sysmex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sysmex stock

FCF Conversion Rate (FCF/EBITDA) of Sysmex is 115.48 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Sysmex changed from 109.97 % to 115.48 %, representing a 5.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Sysmex since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Sysmex with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Sysmex

All Key Metrics — Sysmex